Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 6,039Xls
2D Structure
Also known as: 286930-03-8, Toviaz, (r)-fesoterodine fumarate, Spm 907, Spm 8272, Spm-907
Molecular Formula
C30H41NO7
Molecular Weight
527.6  g/mol
InChI Key
MWHXMIASLKXGBU-RNCYCKTQSA-N
FDA UNII
EOS72165S7

Fesoterodine Fumarate is the fumarate salt form of fesoterodine, a competitive muscarinic receptor antagonist with muscle relaxant and urinary antispasmodic properties. Fesoterodine is rapidly hydrolyzed in vivo into its active metabolite 5-hydroxy methyl tolterodine, which binds and inhibits muscarinic receptors on the bladder detrusor muscle, thereby preventing bladder contractions or spasms caused by acetylcholine. This results in the relaxation of bladder smooth muscle and greater bladder capacity, in addition to a reduction in involuntary muscle contractions and involuntary loss of urine. The active metabolite does not interact with alpha-adrenergic, serotonergic, histaminergic and excitatory amino acid receptors and is eliminated via renal excretion.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(E)-but-2-enedioic acid;[2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate
2.1.2 InChI
InChI=1S/C26H37NO3.C4H4O4/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6;5-3(6)1-2-4(7)8/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t23-;/m1./s1
2.1.3 InChI Key
MWHXMIASLKXGBU-RNCYCKTQSA-N
2.1.4 Canonical SMILES
CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2.C(=CC(=O)O)C(=O)O
2.1.5 Isomeric SMILES
CC(C)C(=O)OC1=C(C=C(C=C1)CO)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.C(=C/C(=O)O)\C(=O)O
2.2 Other Identifiers
2.2.1 UNII
EOS72165S7
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Fesoterodine

2. Toviaz

2.3.2 Depositor-Supplied Synonyms

1. 286930-03-8

2. Toviaz

3. (r)-fesoterodine Fumarate

4. Spm 907

5. Spm 8272

6. Spm-907

7. Spm-8272

8. Fesoterodine Maleate

9. Fesoterodine (fumarate)

10. Eos72165s7

11. (e)-but-2-enedioic Acid;[2-[(1r)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate

12. Propanoic Acid, 2-methyl-, 2-[(1r)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl Ester, (2e)-2-butenedioate (1:1)

13. 286930-03-8 (fumarate); 286930-02-7 (free Base)

14. Fesoterodine Fumarate [usan]

15. Unii-eos72165s7

16. Fesoterodine Fumarate [usan:jan]

17. (e)-but-2-enedioic Acid,[2-[(1r)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate

18. Toviaz (tn)

19. (r)-fesoterodinefumarate

20. Mls003915638

21. Schembl814971

22. Fesoterodine Fumarate - Toviaz

23. Schembl1993632

24. Chembl1201765

25. Dtxsid00904655

26. Bcpp000231

27. Fesoterodine Fumarate (jan/usan)

28. Fesoterodine Fumarate [mi]

29. Hms3884d11

30. Fesoterodine Fumarate [jan]

31. Amy37611

32. Hy-a0030

33. Bdbm50248002

34. Fesoterodine Fumarate [vandf]

35. Mfcd12756004

36. S2240

37. Fesoterodine Fumarate [mart.]

38. Akos005146248

39. Akos015855886

40. Fesoterodine Fumarate [who-dd]

41. Ac-3486

42. Bcp9000682

43. Ccg-269901

44. Cs-0822

45. Ks-1298

46. 2-((1r)-3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl Isobutyrate

47. Fesoterodine Fumarate [ema Epar]

48. 2-((1r)-3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl 2-methylpropanoate Hydrogen (2e)-butenedioate (salt)

49. Propanoic Acid, 2-methyl-, 2-((1r)-3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl Ester, (2e)-2-butenedioate (1:1) (salt)

50. Smr002544691

51. Fesoterodine Fumarate [orange Book]

52. Pf-00695838

53. D08923

54. 930f038

55. A846296

56. Q27277274

57. 2-((1r)-3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl 2-methylpropanoate Hydrogen(2e)-butenedioate (salt)

58. Fesoterodinefumarate;(r)-fesoterodine Fumarate;2-methylpropanoic Acid 2-[(1r)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl Ester (2e)-2-butenedioate

59. Propanoic Acid,2-methyl ,2-((1r)-3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl Ester,(2e)-2-butenedioate (1:1)(salt)

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 527.6 g/mol
Molecular Formula C30H41NO7
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count8
Rotatable Bond Count13
Exact Mass527.28830265 g/mol
Monoisotopic Mass527.28830265 g/mol
Topological Polar Surface Area124 Ų
Heavy Atom Count38
Formal Charge0
Complexity610
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count1
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameToviaz
PubMed HealthFesoterodine (By mouth)
Drug ClassesUrinary Antispasmodic
Drug LabelToviaz contains fesoterodine fumarate and is an extended-release tablet. Fesoterodine is rapidly de-esterified to its active metabolite (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, or 5-hydroxymethyl tolterodine, which is a musca...
Active IngredientFesoterodine fumarate
Dosage FormTablet, extended release
RouteOral
Strength8mg; 4mg
Market StatusPrescription
CompanyPfizer

2 of 2  
Drug NameToviaz
PubMed HealthFesoterodine (By mouth)
Drug ClassesUrinary Antispasmodic
Drug LabelToviaz contains fesoterodine fumarate and is an extended-release tablet. Fesoterodine is rapidly de-esterified to its active metabolite (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, or 5-hydroxymethyl tolterodine, which is a musca...
Active IngredientFesoterodine fumarate
Dosage FormTablet, extended release
RouteOral
Strength8mg; 4mg
Market StatusPrescription
CompanyPfizer

4.2 Drug Indication

Treatment of the symptoms (increased urinary frequency and / or urgency and / or urgency incontinence) that may occur in patients with overactive-bladder syndrome.


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Muscarinic Antagonists

Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)


Urological Agents

Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)


5.2 ATC Code

G04BD11